Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on November 6. Andrew ...

The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...

Aptamer's Optimer technology achieves key milestones in genetic medicine delivery, enhancing targeting specificity and ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

DelveInsight's 'Severe Asthma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline severe asthma ...

AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...

AstraZeneca said on Wednesday that to its knowledge an ongoing investigation by Chinese authorities into the company's top ...

Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they've escaped the low-oxygen regions of a tumor.

The AstraZeneca PLC ADR AZN inched 0.01% higher to $71.43 Monday, on what proved to be an all-around grim trading session for ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class.The ...